These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

692 related articles for article (PubMed ID: 32058248)

  • 1. Legal requirements and recommendations to prescribe naloxone.
    Haffajee RL; Cherney S; Smart R
    Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
    Davis CS; Carr D
    Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing landscape of naloxone availability in the United States, 2011 - 2017.
    Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
    Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States.
    Lambdin BH; Davis CS; Wheeler E; Tueller S; Kral AH
    Drug Alcohol Depend; 2018 Jul; 188():370-376. PubMed ID: 29776688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescriber and pharmacist understanding of revised Rhode Island pain management regulations.
    Rogala BG; Jarvais A; Ng T; Bratberg J
    J Oncol Pharm Pract; 2021 Apr; 27(3):601-608. PubMed ID: 32517637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.
    Barenie RE; Gagne JJ; Kesselheim AS; Pawar A; Tong A; Luo J; Bateman BT
    Drug Saf; 2020 Jul; 43(7):669-675. PubMed ID: 32180134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists.
    Lim JK; Bratberg JP; Davis CS; Green TC; Walley AY
    J Addict Med; 2016; 10(5):300-8. PubMed ID: 27261669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between naloxone prescribing and opioid overdose among patients with acute and chronic pain conditions.
    Qeadan F; Madden EF
    Addiction; 2022 Feb; 117(2):457-471. PubMed ID: 34286895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioid-overdose laws association with opioid use and overdose mortality.
    McClellan C; Lambdin BH; Ali MM; Mutter R; Davis CS; Wheeler E; Pemberton M; Kral AH
    Addict Behav; 2018 Nov; 86():90-95. PubMed ID: 29610001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State legal innovations to encourage naloxone dispensing.
    Davis C; Carr D
    J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statewide Policy to Increase Provision of Take-Home Naloxone at Emergency Department Visits for Opioid Overdose, Rhode Island, 2018‒2019.
    Griffith J; Yorlets RR; Chambers LC; Davis CS; Wentz A; Beaudoin FL; Baird J; Samuels EA
    Am J Public Health; 2023 Apr; 113(4):372-377. PubMed ID: 36745856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicaid prescription limits and their implications for naloxone accessibility.
    Roberts AW; Look KA; Trull G; Carpenter DM
    Drug Alcohol Depend; 2021 Jan; 218():108355. PubMed ID: 33309522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States.
    Smart R; Pardo B; Davis CS
    Addiction; 2021 Jan; 116(1):6-17. PubMed ID: 32533570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-prescribing naloxone does not increase liability risk.
    Davis CS; Burris S; Beletsky L; Binswanger I
    Subst Abus; 2016; 37(4):498-500. PubMed ID: 27648764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event.
    Alexander M; Hooker J; Stratton M; Huh M; Houck K
    J Am Pharm Assoc (2003); 2024; 64(3):101999. PubMed ID: 38151200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021.
    Chua KP; Dahlem CHY; Nguyen TD; Brummett CM; Conti RM; Bohnert AS; Dora-Laskey AD; Kocher KE
    Ann Emerg Med; 2022 Mar; 79(3):225-236. PubMed ID: 34802772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.